MannKind Corp. reported a narrower third-quarter loss than analysts projected, but reported higher operating costs as the company prepares for another round of clinical trials on its inhaled insulin drug. The Valencia biotech reported a net loss of $42.8 million (-22 cents a share), compared with a loss of $38.4 million (-31 cents) in the same period a year earlier. The company reported $35,000 in revenue, compared with no revenue a year earlier. Total operating expenses rose 8 percent to $35.5 million. The company attributed the increase to $7 million in clinical-trial related costs offset by a canceled contract. The company had $2.1 million in cash and short-term investments, not including $86 million raised from a dilutive public offering of common stock and warrants in October. MannKind, which has been struggling to get its Afrezza insulin inhaler approved by the Food and Drug Administration, plans to resubmit the device for approval in the third quarter of next year, following the completion of two additional clinical trials. MannKind gained 5 cents, or less than 3 percent, to close Friday at $1.98 on the Nasdaq.